Selmod is a Swiss biotech start-up that is dedicated to developing innovative antibiotics to combat life-threatening, multi-drug resistant infections. As a brand, Selmod focuses on Selective Mode Antimicrobial Resistance Therapeutics. They aim to tackle the critical issue of antimicrobial resistance by discovering and early clinically developing small molecules and peptides that target new mechanisms of action or established and validated targets.

At Selmod, their priority is to address the urgent need for new antibiotics to combat resistant infections. Their team is highly skilled and motivated to make a significant impact in the field of antimicrobial resistance. With a strong pipeline of promising compounds, Selmod is working diligently to discover and develop effective treatments for these life-threatening infections.

To stay updated on their progress and breakthroughs, interested individuals can sign up for the Selmod Newsletter. For any inquiries or further information, the Selmod GmbH headquarters can be found at Dornacherstrasse 120, Basel, Switzerland. With their dedication to combating antimicrobial resistance, Selmod is striving to save lives and improve global health